AbbVie Inc. (VIE:ABBV)

Market Cap	347.37B
Revenue (ttm)	49.67B
Net Income (ttm)	3.17B
Shares Out	n/a
EPS (ttm)	1.79
PE Ratio	109.58
Forward PE	19.47
Dividend	5.86 (2.93%)
Ex-Dividend Date	Oct 15, 2025

Volume	n/a
Average Volume	3
Open	199.80
Previous Close	200.50
Day's Range	199.60 - 202.50
52-Week Range	149.00 - 207.50
Beta	n/a
RSI	52.70
Earnings Date	Oct 29, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: ABBV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD